Drug Database
VA

varicella zoster vaccine

✓ Approved

HK inno.N · Vaccine · Vaccine

What is varicella zoster vaccine?

varicella zoster vaccine is a vaccine developed by HK inno.N. It is approved for therapeutic indications via injectable (others).

Drug Profile

CompanyHK inno.N
Drug ClassVaccine, Large Molecules
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, HK inno.N

Therapeutic Indications

varicella zoster vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsVaricella zoster virus infection✓ Approved

Related Research Articles

PubMedJournal of endodontics2026-07-17

Herpes Zoster Ophthalmicus Following Endodontic Treatment: A Case Report.

Altundaşar Emre E, Derinler Nevran N, Pierovi Nilsu N

Herpes zoster ophthalmicus, resulting from varicella-zoster virus reactivation along the ophthalmic division of the trigeminal nerve, is a rare but potentially sight-threatening condition that warrants awareness in clinical dental practice. A 36-year-old male presented three days after nonsurgical root canal treatment of the right maxillary first molar with severe migraine-like neuropathic pain, unilateral vesiculobullous eruptions along the V1 dermatome, periorbital edema, and conjunctival hyperemia. The treated tooth exhibited no remarkable clinical or radiographic findings. Dermatological evaluation confirmed herpes zoster ophthalmicus, and systemic antiviral therapy resulted in complete resolution by the six-month follow-up. This case underscores the need to broaden the differential diagnosis when post-endodontic symptoms are disproportionate to or inconsistent with clinical findings. Early recognition and prompt referral are critical in preventing vision-threatening complications.

PMID 42462810
Read full article →
PubMedCureus2026-07-17

Incidence and Clinical Characteristics of Herpes Zoster in Patients With Spondyloarthritis Receiving Biologic Therapy: A 36-Month Multicenter Registry-Based Study.

Ben Marzouk Ilham I, Rostom Samira S, El Binoune Imane I, Ghoullam Ghizlane G et al.

Herpes zoster, caused by the reactivation of varicella-zoster virus, has been reported in patients with autoimmune inflammatory diseases receiving biologic therapies. However, data regarding its occurrence in patients with spondyloarthritis (SpA) remain limited. This study aimed to determine the incidence of herpes zoster and describe the clinical characteristics of affected patients with SpA receiving biologic therapy. A multicenter retrospective registry-based study was conducted over a 36-month period, including patients with SpA receiving biologic therapy and registered in the Moroccan Society of Rheumatology Biotherapy Registry (BRMSR). Clinical, laboratory data, including erythrocyte sedimentation rate and C-reactive protein, and therapeutic data were collected at baseline, at 36 months, and at the time of herpes zoster infection. A descriptive statistical analysis was performed. A total of 194 patients with SpA were included, with a mean age of 40.23 ± 13.68 years. The cohort included 123 males (63.4%) and 71 females (36.6%), with a mean disease duration of 11 ± 7 years. Most patients (98.5%) were treated with anti-tumor necrosis factor agents, with etanercept being the most commonly prescribed biologic therapy. The incidence of herpes zoster was 6.87 cases per 1,000 person-years (95% CI: 2.018-16.85). Four cases of herpes zoster were identified. These patients were all older than 55 years, had associated comorbidities, and had prolonged exposure to biologic therapy. The incidence of herpes zoster in patients with SpA receiving biologic therapy was low. The four reported cases shared common clinical characteristics, including older age, the presence of comorbidities, and prolonged exposure to biologic therapy. Further studies with larger populations and longer follow-up are needed to better characterize herpes zoster occurrence in this population.

PMID 42465193
Read full article →
PubMedbioRxiv : the preprint server for biology2026-07-17

Exposure to P. falciparum and common cold viruses shape vaccine responses in early life.

Bach Florian F, Sigal George G, Wohlstadter Jacob J, Brown Rayven R et al.

Vaccine immunogenicity is consistently lower in low-income countries than in high-income settings, yet the factors driving this disparity remain incompletely understood. Using multiplexed electrochemiluminescence serology, we measured IgG and IgA responses to Expanded Program on Immunization (EPI) vaccines and common childhood viral infections in 89 Ugandan infants. We integrated detailed parasitological surveillance and maternal clinical data to examine how P. falciparum infection history, concurrent parasitemia, maternal gravidity, and early-life viral exposures shaped serological profiles. We found that infants mounted robust responses to most EPI vaccines, but critical gaps in protection persisted for diphtheria, measles and rubella. Children born to primigravid mothers had lower antibody levels at 8 weeks of age, independent of placental malaria and only partially explained by maternal age. Contrary to expectation, cumulative P. falciparum exposure was positively associated with antibody concentrations to diphtheria and varicella, and concurrent parasitemia was positively correlated with responses to multiple antigens. Seroconversion to rhinovirus C was associated with higher IgG and IgA levels to several vaccines. Together, these findings suggest that common microbial exposures during infancy, including respiratory viruses and P. falciparum may positively modulate vaccine responsiveness.

PMID 42465441
Read full article →
PubMedThe Journal of general virology2026-07-17

Human pegivirus, Toscana virus and herpesviruses identified in cerebrospinal fluid from adults with unexplained neurologic disease, Spain, 2022-2023.

Donoso Ana A, Pérez Ana Belén AB, Lopez-Dosil Marcos M, Vázquez Ana A et al.

Viral central nervous system (CNS) infections in adults frequently remain unresolved after routine diagnostic testing. We applied probe-based viral metagenomic next-generation sequencing (vmNGS) to cerebrospinal fluid samples from adults with suspected CNS infection and negative conventional diagnostics in a retrospective multicentre study conducted in Spain between 2022 and 2023. Among 40 idiopathic cases, vmNGS detected viral sequences in 6 patients without evidence of coinfection: human pegivirus (HPgV, n=3), Toscana virus (TOSV, n=1), herpes simplex virus type 1 (HSV-1, n=1) and varicella-zoster virus (VZV, n=1). Two HPgV-positive patients were transplant recipients, with neurological disease occurring more than 2 years after transplantation, compatible with possible long-term viral persistence in immunocompromised hosts. TOSV genotype B was identified in a patient residing in central Spain, supporting consideration of TOSV in selected cases of unexplained aseptic meningitis during the vector season, including outside traditionally recognized Mediterranean coastal regions. Furthermore, the failure of syndromic panel testing to detect HSV-1 and VZV highlights the need for complementary diagnostic strategies when clinical suspicion remains high. Overall, the detection of unexpected viral sequences, together with missed clinically actionable infections, supports the use of complementary molecular testing in selected cases of unexplained CNS syndromes when routine diagnostics are negative. These findings highlight the added diagnostic value of vmNGS and provide sequence-level data for future studies of viral diversity and molecular epidemiology in neurological disease.

PMID 42467473
Read full article →
PubMedPM & R : the journal of injury, function, and rehabilitation2026-07-17

Effects of adjustable-volume transfemoral prosthetic sockets on balance and falls: A randomized clinical trial.

Gates Deanna H DH, Wensman Jeffrey J, Gutierrez Anthony R AR, Kartes Jordan J et al.

Adjustable-volume prosthetic sockets have been developed to allow users to accommodate volume fluctuations throughout the day. Improvement in socket fit is thought to enhance the connection between the user's residual limb and prosthesis and may therefore improve postural control and balance. However, no studies have assessed balance-related outcomes or falls between different adjustable socket designs. To compare balance-related outcomes for people with transfemoral limb loss using three styles of adjustable-volume sockets and a laminated socket. Randomized clinical trial. Prosthetics clinics and research laboratories. A convenience sample of 29 individuals with unilateral transfemoral amputation were recruited, of whom 23 completed testing in at least one adjustable-volume socket and were included. Participants completed four 4-week trials with each of three adjustable-volume prosthetic sockets and a laminated socket, in random order. Adjustable-volume sockets included Infinite (LIM Innovations, San Francisco, CA, USA), CJ (CJ Sockets Technologies, Beverly, MA, USA), and Quatro (Quorum, Windsor, CO, USA). The primary outcomes were self-reported balance, number of falls and stumbles, and balance confidence. Secondary outcomes included the Narrow Beam Walk Test (NBWT) and Timed Up and Go Test (TUG). Surveys were conducted after at least 3 weeks of use of each socket, and functional measures were collected after 4 weeks. There were no main effects of socket type on self-reported balance (p = .316), balance confidence (p = .963), NBWT (p = .159), or TUG (p = .581). Eighteen participants (78%) reported falling or stumbling at least once in a 3-week period in at least one socket condition. There were no differences in the proportion of fallers (1+ falls) or stumblers (1+ stumbles) between the laminated condition and any adjustable-socket condition (p > .210). The adjustable-volume prosthetic sockets tested demonstrated comparable performance to laminated sockets for balance and fall-related outcomes. The high number of falls and stumbles reported suggests that future studies should focus on balance and falls training, acknowledging that changes to the socket may be insufficient to address this issue.

PMID 42464056
Read full article →
PubMedClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026-07-17

Artificial Intelligence Across the Vaccine Clinical Trial Lifecycle: Evidence, Readiness, and Guardrails.

Idriss Jad J, Kalash Suha S, Faraj Jana Abu JA, Nolan Lauren L et al.

Artificial intelligence (AI) is increasingly being used to support clinical research, but its value in vaccine clinical trials requires careful evidence-based assessment. Vaccine trials pose distinctive challenges, including high safety expectations in healthy participants, evolving pathogen exposure and baseline immunity, incomplete correlates of protection, applicability of findings to intended-use populations, and intense public scrutiny. We conducted a structured, vaccine-focused narrative review of AI applications across the vaccine trial lifecycle, supplemented by targeted clinical trial and vaccine pharmacovigilance studies with directly transferable methods. In the combined evidence base, evidence is strongest for operational uses, particularly recruitment, eligibility screening, trial matching, and risk-based monitoring. Applications to immune-response interpretation, correlates of protection, and vaccine safety surveillance are promising but remain less prospectively validated. Responsible adoption should be guided by intended tool use, evidence of strength, data governance, regulatory expectations, and preservation of human scientific and safety judgment.

PMID 42464875
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about varicella zoster vaccine